Cargando…
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few da...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033040/ https://www.ncbi.nlm.nih.gov/pubmed/35454151 http://dx.doi.org/10.3390/biom12040562 |
_version_ | 1784692792981716992 |
---|---|
author | Toscano, Arianna Cinquegrani, Maria Scuruchi, Michele Di Pino, Antonino Piro, Salvatore Ferrara, Viviana Morace, Carmela Lo Gullo, Alberto Imbalzano, Egidio Purrello, Francesco Squadrito, Giovanni Scicali, Roberto Mandraffino, Giuseppe |
author_facet | Toscano, Arianna Cinquegrani, Maria Scuruchi, Michele Di Pino, Antonino Piro, Salvatore Ferrara, Viviana Morace, Carmela Lo Gullo, Alberto Imbalzano, Egidio Purrello, Francesco Squadrito, Giovanni Scicali, Roberto Mandraffino, Giuseppe |
author_sort | Toscano, Arianna |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few data exist regarding the role of PCSK9 in vascular damage. We aimed to evaluate the impact of PCSK9 plasma levels on pulse wave velocity (PWV) and the effect of PCSK9 inhibitors (PCSK9-i) on circulating PCSK9 and PWV in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. In a previous step, HeFH patients were enrolled and LLT was prescribed according to guidelines. Biochemical analyses and PWV assessment were performed at baseline (T0), after 6 months of high-efficacy statin plus ezetimibe (T1) and after 6 months of PCSK9-i (T2). The PCSK9 levels were evaluated in 26 selected HeFH subjects at the three time points and 26 healthy subjects served as controls for the reference value for PCSK9 plasma levels. The PWV values decreased at each time point in HeFH subjects after LLT starting (8.61 ± 2.4 m/s, −8.7%; p < 0.001 vs. baseline at T1, and 7.9 ± 2.1 m/s, −9.3%; p < 0.001 vs. both T1 and baseline) and it was correlated to PCSK9 (r = 0.411, p = 0.03). The PCSK9 levels increased on statin/EZE therapy (+42.8% at T1) while it decreased after PCSK9-i was started (−34.4% at T2). We noted a significant relationship between PCSK9 levels and PWV changes at T1 and T2. In conclusion, PCSK9 levels were associated with baseline PWV values in HeFH subjects; moreover, we found that PCSK9 level variations seemed to be correlated with PWV changes on LLT. A longer observation time and wider sample size are needed to assess the potential role of PCSK9 plasma levels on the vascular function and remodelling, and to clarify the effects of PCSK9-i in these pathways. |
format | Online Article Text |
id | pubmed-9033040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90330402022-04-23 PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy Toscano, Arianna Cinquegrani, Maria Scuruchi, Michele Di Pino, Antonino Piro, Salvatore Ferrara, Viviana Morace, Carmela Lo Gullo, Alberto Imbalzano, Egidio Purrello, Francesco Squadrito, Giovanni Scicali, Roberto Mandraffino, Giuseppe Biomolecules Article Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few data exist regarding the role of PCSK9 in vascular damage. We aimed to evaluate the impact of PCSK9 plasma levels on pulse wave velocity (PWV) and the effect of PCSK9 inhibitors (PCSK9-i) on circulating PCSK9 and PWV in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. In a previous step, HeFH patients were enrolled and LLT was prescribed according to guidelines. Biochemical analyses and PWV assessment were performed at baseline (T0), after 6 months of high-efficacy statin plus ezetimibe (T1) and after 6 months of PCSK9-i (T2). The PCSK9 levels were evaluated in 26 selected HeFH subjects at the three time points and 26 healthy subjects served as controls for the reference value for PCSK9 plasma levels. The PWV values decreased at each time point in HeFH subjects after LLT starting (8.61 ± 2.4 m/s, −8.7%; p < 0.001 vs. baseline at T1, and 7.9 ± 2.1 m/s, −9.3%; p < 0.001 vs. both T1 and baseline) and it was correlated to PCSK9 (r = 0.411, p = 0.03). The PCSK9 levels increased on statin/EZE therapy (+42.8% at T1) while it decreased after PCSK9-i was started (−34.4% at T2). We noted a significant relationship between PCSK9 levels and PWV changes at T1 and T2. In conclusion, PCSK9 levels were associated with baseline PWV values in HeFH subjects; moreover, we found that PCSK9 level variations seemed to be correlated with PWV changes on LLT. A longer observation time and wider sample size are needed to assess the potential role of PCSK9 plasma levels on the vascular function and remodelling, and to clarify the effects of PCSK9-i in these pathways. MDPI 2022-04-09 /pmc/articles/PMC9033040/ /pubmed/35454151 http://dx.doi.org/10.3390/biom12040562 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Toscano, Arianna Cinquegrani, Maria Scuruchi, Michele Di Pino, Antonino Piro, Salvatore Ferrara, Viviana Morace, Carmela Lo Gullo, Alberto Imbalzano, Egidio Purrello, Francesco Squadrito, Giovanni Scicali, Roberto Mandraffino, Giuseppe PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy |
title | PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy |
title_full | PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy |
title_fullStr | PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy |
title_full_unstemmed | PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy |
title_short | PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy |
title_sort | pcsk9 plasma levels are associated with mechanical vascular impairment in familial hypercholesterolemia subjects without a history of atherosclerotic cardiovascular disease: results of six-month add-on pcsk9 inhibitor therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033040/ https://www.ncbi.nlm.nih.gov/pubmed/35454151 http://dx.doi.org/10.3390/biom12040562 |
work_keys_str_mv | AT toscanoarianna pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT cinquegranimaria pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT scuruchimichele pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT dipinoantonino pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT pirosalvatore pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT ferraraviviana pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT moracecarmela pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT logulloalberto pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT imbalzanoegidio pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT purrellofrancesco pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT squadritogiovanni pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT scicaliroberto pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy AT mandraffinogiuseppe pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy |